Font Size: A A A
State to follow ACIP recommendation on Janssen COVID-19 vaccine

Carson City, NV – Today, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) announced they would lift the recommended pause on the one-shot Janssen COVID-19 vaccine that was under review for rare but serious reactions.

The CDC and FDA announcement follows a recommendation by the CDC’s Advisory Committee on Immunization Practices (ACIP).

The State of Nevada will follow the recommendation and the Nevada State Immunization Program will begin notifying vaccinating partners to resume use of the Janssen vaccine doses in their inventory.

Earlier this month the FDA and CDC issued a joint statement recommending a pause in the use of the vaccine. People who have received the Janssen vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are required to report adverse events to the Vaccine Adverse Event Reporting System at

Immunize Nevada

Immunize Nevada, an award winning 501c3 non profit, is widely recognized as Nevada’s trusted resource for immunizations and community health for all ages by fostering education and statewide collaboration.